EMERGENT BIOSOLUTIONS INC. Payments to Acquire Debt Securities, Available-for-sale
EMERGENT BIOSOLUTIONS INC. (EBS) reported Payments to Acquire Debt Securities, Available-for-sale of $0 for the 12-month period ending 2013-12-31, per its 10-K filed 2014-03-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2014-03-10
- EMERGENT BIOSOLUTIONS INC. payments to acquire debt securities, available-for-sale for the quarter ending 2012-12-31 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payments to acquire debt securities, available-for-sale for the quarter ending 2012-09-30 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payments to acquire debt securities, available-for-sale for the quarter ending 2012-06-30 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. payments to acquire debt securities, available-for-sale for the quarter ending 2012-03-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. payments to acquire debt securities, available-for-sale for fiscal 2013 was $0.00.
- EMERGENT BIOSOLUTIONS INC. payments to acquire debt securities, available-for-sale for fiscal 2012 was $0.00, a 100.00% decline from fiscal 2011.
- EMERGENT BIOSOLUTIONS INC. payments to acquire debt securities, available-for-sale for fiscal 2011 was $4.19M.
- EMERGENT BIOSOLUTIONS INC. payments to acquire debt securities, available-for-sale for fiscal 2010 was $0.00.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2013-12-31 | $0.00 10-K · filed 2014-03-10 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $0.00 derived: sum of 2 quarters · filed 2014-03-10 | $0.00 derived: sum of 3 quarters · filed 2014-03-10 | $0.00 10-K · filed 2014-03-10 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $0.00 derived: sum of 2 quarters · filed 2012-11-01 | $0.00 10-Q · filed 2012-11-01 | -$1.03M derived: sum of 4 quarters · filed 2014-03-10 |
| 2012-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $0.00 10-Q · filed 2012-08-03 | -$1.03M derived: sum of 3 quarters · filed 2014-03-10 | -$1.08M derived: sum of 4 quarters · filed 2014-03-10 |
| 2012-03-31 | $0.00 10-Q · filed 2012-05-04 | -$1.03M derived: sum of 2 quarters · filed 2014-03-10 | -$1.08M derived: sum of 3 quarters · filed 2014-03-10 | -$122.00K derived: sum of 4 quarters · filed 2014-03-10 |
| 2011-12-31 | -$1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | -$1.08M derived: sum of 2 quarters · filed 2014-03-10 | -$122.00K derived: sum of 3 quarters · filed 2014-03-10 | $4.19M 10-K · filed 2014-03-10 |
| 2011-09-30 | -$49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $911.00K derived: sum of 2 quarters · filed 2012-11-01 | $5.22M 10-Q · filed 2012-11-01 | $5.22M derived: sum of 4 quarters · filed 2013-03-08 |
| 2011-06-30 | $960.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03 | $5.27M 10-Q · filed 2012-08-03 | $5.27M derived: sum of 3 quarters · filed 2013-03-08 | $5.27M derived: sum of 4 quarters · filed 2013-03-08 |
| 2011-03-31 | $4.31M 10-Q · filed 2012-05-04 | $4.31M derived: sum of 2 quarters · filed 2013-03-08 | $4.31M derived: sum of 3 quarters · filed 2013-03-08 | |
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | $0.00 derived: sum of 2 quarters · filed 2013-03-08 | $0.00 10-K · filed 2013-03-08 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04 | $0.00 10-Q · filed 2011-11-04 | ||
| 2010-06-30 | $0.00 10-Q · filed 2011-08-05 | |||
| 2009-12-31 | $0.00 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |